Changes in the pharmacokinetics of diclofenac in rheumatological patients taking complex treatment.

Abstract

The aim of the study was to study in a comparative aspect some of the pharmacokinetics of Diclofenac sodium in patients with rheumatoid arthritis with impaired gastric microbiocenosis (gastric dysbiosis) and without disturbance (without dysbiosis). Material and methods: We examined 38 patients aged 18 to 60 years, with I-II-III degree of disease activity. In addition to general clinical examination conductedenzyme immunoassay and urease test to determine Helicobacter pylori andhigh performance liquid chromatography to determine the pharmacokinetics of diclofenac. Results: studies and analysis of their results indicate that in conditions of rheumatoid arthritis, in particular, in the presence of comorbid conditions, there is a decrease in the metabolic rate and lengthening the half-life of NSAIDs, which increases the risk of side effects, especially from the gastrointestinal tract and significantly affects the course of the disease and treatment results.